Commercial application of limonenyldihydroxybenzyl ethoxycarbonyl azetidine (LEA) for oxidative stress reduction
Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine (LEA) has demonstrated preclinical efficacy in reducing oxidative stress, showing significant inhibition of inflammatory cytokines in human dermal fibroblasts. LEA is positioned for further development to protect both plants and humans from UVA and UVB radiation.
Overview
Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine (LEA) is a promising compound targeting oxidative stress, a condition affecting both plants and humans. Preclinical studies have shown that LEA effectively inhibits inflammatory cytokines such as IL-6 and IL-1β, which are elevated due to oxidative stress from UVA and UVB radiation. The compound has demonstrated significant efficacy in human dermal fibroblasts, achieving up to 97% inhibition of IL-6 and 100% inhibition of IL-1β, indicating its potential in cosmetic and therapeutic applications for skin protection and anti-aging.
Technical specifications
- Compound: Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine (LEA)
- Efficacy:
- UVA-induced photoaging: 95% max IL-6 inhibition with an IC50 of 0.9 micromolar
- UVB-induced inflammatory response: 97% max IL-6 inhibition with an IC50 of 3 micromolar; 100% max IL-1β inhibition with an IC50 of 0.078 nanomolar
- Applications: Potential use in protecting skin from photoaging and oxidative stress, with ongoing research into agricultural applications.
Technology readiness level
LEA is currently at Technology Readiness Level 4, having been validated in laboratory environments. The next steps include further validation for protecting plant species against UV radiation and additional testing in relevant environments.
About Kannalife Sciences, Inc.
Kannalife Sciences, Inc. is a biopharmaceutical company based in Doylestown, Pennsylvania, that specializes in the research and development of synthetic, cannabidiol-inspired therapeutics. A subsidiary of Neuropathix, Inc., the company focuses on creating small molecule drug candidates designed to address neuroinflammation, neuropathic pain, and neurodegenerative diseases. By utilizing proprietary technology to synthesize novel compounds, such as its lead candidate KLS-13019, Kannalife aims to optimize bioavailability and therapeutic potency to treat conditions including Parkinson’s disease, hepatic encephalopathy, and chemotherapy-induced peripheral neuropathy.
These therapeutic efforts aim to provide patients with alternatives to traditional treatments, including non-opioid options for pain management and solutions for complex neurological disorders. The company’s work is supported by strategic grants from organizations such as the National Institutes of Health and The Michael J. Fox Foundation, alongside partnerships with research institutions and pharmaceutical service providers. Through its commitment to rigorous pre-clinical development and a portfolio of patented molecular entities, Kannalife seeks to improve cellular health and address significant unmet medical needs in neurological health.
delivered to your inbox.